Compare · BAX vs BDX
BAX vs BDX
Side-by-side comparison of Baxter International Inc. (BAX) and Becton Dickinson and Company (BDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BAX and BDX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $49.29B, about 4.2x BAX ($11.79B).
- Over the past year, BAX is down 0.1% and BDX is down 3.1% - BAX leads by 3.0 points.
- BAX has been more active in the news (4 items in the past 4 weeks vs 2 for BDX).
- Both have 25 recent analyst ratings on file.
- Company
- Baxter International Inc.
- Becton Dickinson and Company
- Price
- $22.79-1.02%
- $180.78-0.29%
- Market cap
- $11.79B
- $49.29B
- 1M return
- -14.55%
- -3.65%
- 1Y return
- -0.09%
- -3.09%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 4
- 2
- Recent ratings
- 25
- 25
Baxter International Inc.
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Latest BAX
- New insider Heine Bernard claimed ownership of 32,840 shares (SEC Form 3)
- President and CEO Hider Andrew P. covered exercise/tax liability with 54,276 shares, decreasing direct ownership by 9% to 518,447 units (SEC Form 4)
- President, CCS Teaff James covered exercise/tax liability with 750 shares, decreasing direct ownership by 2% to 30,370 units (SEC Form 4)
- President, Front Line Care Foster Julie covered exercise/tax liability with 2,098 shares, decreasing direct ownership by 7% to 29,164 units (SEC Form 4)
- Baxter International Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Baxter Appoints John Rogers Chief Financial Officer
- Baxter International Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- Baxter Announces Pricing for Its Upsized Cash Tender Offers
- Baxter Announces Early Tender Results and Upsizing of Previously Announced Cash Tender Offers
- SEC Form 8-K filed by Baxter International Inc.
Latest BDX
- BD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at Fairview
- EVP & Chief Financial Officer Roque Vitor covered exercise/tax liability with 190 shares, decreasing direct ownership by 2% to 8,041 units (SEC Form 4) (withholding tax)
- EVP, Chief Revenue Officer Feld Michael sold $31,101 worth of shares (165 units at $188.49) as part of a pre-agreed trading plan, decreasing direct ownership by 0.83% to 19,720 units (SEC Form 4)
- BD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical Innovation
- BD to Present at Wells Fargo 21st Annual Healthcare Conference
- EVP, Chief Revenue Officer Feld Michael covered exercise/tax liability with 1,049 shares, decreasing direct ownership by 5% to 19,885 units (SEC Form 4) (for withholding tax)
- BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
- Chairman, CEO and President Polen Thomas E Jr exercised 43,278 shares at a strike of $167.25, returned $7,238,310 worth of shares to the company (39,126 units at $185.00) and sold $768,120 worth of shares (4,152 units at $185.00) as part of a pre-agreed trading plan (SEC Form 4)
- EVP and President, EMEA Goette Roland sold $440,888 worth of shares (2,438 units at $180.84), decreasing direct ownership by 14% to 14,856 units (SEC Form 4)
- BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial